Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

CAR T-cell therapy stories

Oct 23, 2026

Bristol Myers patient died after CAR-T treatment, company explains June trial pause

Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.

Oct 23, 2026·5 sources
00
Oct 15, 2026

Armed Cell Therapeutics acquires Galapagos CAR-T therapies from Lakefront Biotherapeutics

Armed Cell Therapeutics, a Belgian startup chaired by former Galapagos CEO Paul Stoffels, has acquired the CAR-T cell therapy assets that Lakefront Biotherapeutics (formerly Galapagos) divested during its strategic overhaul. The deal allows Stoffels to continue developing the cancer cell therapies he had championed during his tenure at Galapagos.

Oct 15, 2026·3 sources
00
Oct 6, 2026

Caribou Biosciences halts CAR-T programs and seeks strategic alternatives after failing to secure funding

Caribou Biosciences, a CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, announced it will discontinue its two allogeneic CAR-T cell therapy programs and lay off staff after failing to secure funding for a pivotal lymphoma trial. The company's stock plunged 40% following the announcement as it explores strategic alternatives.

Oct 6, 2026·7 sources
00
Oct 5, 2026

International panel updates guidelines for CAR T-cell therapy in autoimmune disease

An international multidisciplinary group of 31 experts coordinated by EBMT, ISCT, and JACIE has released updated consensus recommendations for using CAR T-cell therapy in patients with severe, treatment-refractory autoimmune diseases. The guidelines, originally released in 2024, include recommendations around optimizing safety.

Oct 5, 2026·3 sources
00
Sep 28, 2026

Adicet Bio's off-the-shelf CAR-T therapy shows promise in lupus trial

Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.

Sep 28, 2026·4 sources
00

Three deaths in Novartis CAR T-cell therapy trials for autoimmune disease prompt caution

Three participants have died in clinical trials of Novartis' chimeric antigen receptor T-cell therapy for autoimmune disease, prompting physicians to approach patient discussions with greater caution as the field remains in early stages of development.

Sep 28, 2026·3 sources
00
Sep 8, 2026

Bristol Myers CAR-T therapy shows high response rate in treatment-resistant blood cancer

Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.

Sep 8, 2026·3 sources
00

BrainChild Bio raises $116M series A for pediatric brain cancer CAR-T therapy

BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.

Sep 8, 2026·3 sources
00
Sep 1, 2026

Novartis pauses autoimmune cell therapy trials after three patient deaths

Novartis temporarily halted enrollment and treatment in eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after three patients died. Bristol Myers Squibb programs were also paused.

Sep 1, 2026·3 sources
00
Aug 24, 2026

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00
Aug 12, 2026

Scientists develop genetic tool to make soft tumors vulnerable to CAR-T cell therapy

Researchers at USC have engineered a genetic tool that addresses a major obstacle in cancer immunotherapy by targeting the physical softness of solid tumors, potentially enabling CAR-T cell therapy to work against cancers it previously couldn't treat effectively.

Aug 12, 2026·2 sources
00
Jul 24, 2026

Study Identifies Germline Variants Linked to Yescarta CAR-T Toxicity and Expansion

New research analyzing patients from Kite Pharma's Yescarta clinical trials has identified inherited genetic signatures that can predict which patients are at higher risk for toxic side effects from CAR-T cell therapy, potentially enabling better patient selection and monitoring for this cancer immunotherapy.

Jul 24, 2026·4 sources
00
Jun 22, 2026

China Approves World's First CAR-T Therapy for Solid Tumors to Treat Advanced Gastric Cancer

China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.

Jun 22, 2026·4 sources
00
May 14, 2026

CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines secured $122 million in funding to advance its CAR-T therapy candidates through human trials, alongside a company rebrand and expanded pipeline.

May 14, 2026·1 source
00
Apr 21, 2026

CAR-T Therapy Shows Promise in Preventing Multiple Myeloma in High-Risk Patients

Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.

Apr 21, 2026·2 sources
00

Top claims

  • ▪Bristol Myers Squibb voluntarily paused zolacabtagene autoleucel trials in September 2026 to review safety data after observing transient and reversible inflammatory side effects
  • ▪Most multiple sclerosis patients with sufficient follow-up after receiving zolacabtagene autoleucel showed no new disease activity or worsening disability
  • ▪Bristol Myers Squibb disclosed on October 23, 2026, that a patient in an early-stage multiple sclerosis trial died of septic pneumonia 44 days after receiving experimental CAR-T therapy zolacabtagene autoleucel

Subtopics

Drug Approval and Clinical Trials8Drug Policy, Pricing & Approval8Clinical trials7Cancer immunotherapy5Pharma5Immunotherapy4Autoimmune disease treatments3Cancer & Oncology3Cancer Treatment & Therapies3Hematology & Blood Cancers3Biotechnology2Cancer treatment2Pharmaceutical Industry2AI in cancer treatment1Autoimmune disease1Biomedical research1Biotech startup1Cancer prevention1Cancer treatment breakthroughs1Cancer Types1China1Corporate layoffs1CRISPR gene editing1Drug safety1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories